Prognostic Study of Major Adverse Cardiovascular Events in Patients With Coronary Artery Disease Based on Metabolomics, and Lipidomics (BIPass II)
CompletedOBSERVATIONAL
Enrollment
5,822
Participants
Timeline
Start Date
November 1, 2017
Primary Completion Date
March 1, 2022
Study Completion Date
March 1, 2022
Conditions
Major Adverse Cardiovascular Events in Patients With Coronary Artery Disease
Trial Locations (1)
250012
Yuguo Chen, Jinan
All Listed Sponsors
lead
Qilu Hospital of Shandong University
OTHER
NCT05550805 - Prognostic Study of Major Adverse Cardiovascular Events in Patients With Coronary Artery Disease Based on Metabolomics, and Lipidomics (BIPass II) | Biotech Hunter | Biotech Hunter